Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Quantitative and qualitative changes in anti-Neu5Gc antibody response following rabbit anti-thymocyte IgG induction in kidney allograft recipients

J. Rousse, A. Salama, S. Leviatan Ben-Arye, P. Hruba, J. Slatinska, G. Evanno, O. Duvaux, D. Blanchard, H. Yu, X. Chen, JM. Bach, V. Padler-Karavani, O. Viklicky, JP. Soulillou,

. 2019 ; 49 (4) : e13069. [pub] 20190225

Language English Country Great Britain

Document type Journal Article

Persistent link   https://www.medvik.cz/link/bmc19045061

Grant support
Ministry of Health, Czech Republic-conceptual development of research organization
Health-2013-INNOVATION-1-603049 FP7 Health
62466 Israeli Ministry of Science, Technology and Space

Antibodies of non-human mammals are glycosylated with carbohydrate antigens, such as galactose-α-1-3-galactose (α-Gal) and N-glycolylneuraminic acid (Neu5Gc). These non-human carbohydrate antigens are highly immunogenic in humans due to loss-of-function mutations of the key genes involved in their synthesis. Such immunogenic carbohydrates are expressed on therapeutic polyclonal rabbit anti-human T-cell IgGs (anti-thymocyte globulin; ATG), the most popular induction treatment in allograft recipients. To decipher the quantitative and qualitative response against these antigens in immunosuppressed patients, particularly against Neu5Gc, which may induce endothelial inflammation in both the graft and the host. We report a prospective study of the antibody response against α-Gal and Neu5Gc-containing glycans following rabbit ATG induction compared to controls. We show a drop in the overall levels of anti-Neu5Gc antibodies at 6 and 12 months post-graft compared to the pre-existing levels due to the major early immunosuppression. However, in contrast, in a cross-sectional study there was a highly significant increase in anti-Neu5Gc IgGs levels at 6 months post-graft in the ATG-treated compared to non-treated patients(P = 0.007), with a clear hierarchy favouring anti-Neu5Gc over anti-Gal response. A sialoglycan microarray analysis revealed that the increased anti-Neu5Gc IgG response was still highly diverse against multiple different Neu5Gc-containing glycans. Furthermore, some of the ATG-treated patients developed a shift in their anti-Neu5Gc IgG repertoire compared with the baseline, recognizing different patterns of Neu5Gc-glycans. In contrast to Gal, Neu5Gc epitopes remain antigenic in severely immunosuppressed patients, who also develop an anti-Neu5Gc repertoire shift. The clinical implications of these observations are discussed.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc19045061
003      
CZ-PrNML
005      
20200113152155.0
007      
ta
008      
200109s2019 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.1111/eci.13069 $2 doi
035    __
$a (PubMed)30620396
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Rousse, Juliette $u Xenothera, Nantes, France.
245    10
$a Quantitative and qualitative changes in anti-Neu5Gc antibody response following rabbit anti-thymocyte IgG induction in kidney allograft recipients / $c J. Rousse, A. Salama, S. Leviatan Ben-Arye, P. Hruba, J. Slatinska, G. Evanno, O. Duvaux, D. Blanchard, H. Yu, X. Chen, JM. Bach, V. Padler-Karavani, O. Viklicky, JP. Soulillou,
520    9_
$a Antibodies of non-human mammals are glycosylated with carbohydrate antigens, such as galactose-α-1-3-galactose (α-Gal) and N-glycolylneuraminic acid (Neu5Gc). These non-human carbohydrate antigens are highly immunogenic in humans due to loss-of-function mutations of the key genes involved in their synthesis. Such immunogenic carbohydrates are expressed on therapeutic polyclonal rabbit anti-human T-cell IgGs (anti-thymocyte globulin; ATG), the most popular induction treatment in allograft recipients. To decipher the quantitative and qualitative response against these antigens in immunosuppressed patients, particularly against Neu5Gc, which may induce endothelial inflammation in both the graft and the host. We report a prospective study of the antibody response against α-Gal and Neu5Gc-containing glycans following rabbit ATG induction compared to controls. We show a drop in the overall levels of anti-Neu5Gc antibodies at 6 and 12 months post-graft compared to the pre-existing levels due to the major early immunosuppression. However, in contrast, in a cross-sectional study there was a highly significant increase in anti-Neu5Gc IgGs levels at 6 months post-graft in the ATG-treated compared to non-treated patients(P = 0.007), with a clear hierarchy favouring anti-Neu5Gc over anti-Gal response. A sialoglycan microarray analysis revealed that the increased anti-Neu5Gc IgG response was still highly diverse against multiple different Neu5Gc-containing glycans. Furthermore, some of the ATG-treated patients developed a shift in their anti-Neu5Gc IgG repertoire compared with the baseline, recognizing different patterns of Neu5Gc-glycans. In contrast to Gal, Neu5Gc epitopes remain antigenic in severely immunosuppressed patients, who also develop an anti-Neu5Gc repertoire shift. The clinical implications of these observations are discussed.
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a protilátky $x imunologie $x metabolismus $7 D000906
650    _2
$a studie případů a kontrol $7 D016022
650    _2
$a průřezové studie $7 D003430
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a buněčná imunita $x fyziologie $7 D007111
650    _2
$a imunoglobulin G $x farmakologie $7 D007074
650    _2
$a imunologické faktory $x farmakologie $7 D007155
650    _2
$a transplantace ledvin $x metody $7 D016030
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a kyseliny neuraminové $x imunologie $7 D009438
650    _2
$a prospektivní studie $7 D011446
650    _2
$a thymocyty $x imunologie $7 D060168
650    _2
$a transplantační imunologie $x fyziologie $7 D014181
650    _2
$a homologní transplantace $7 D014184
655    _2
$a časopisecké články $7 D016428
700    1_
$a Salama, Apolline $u Xenothera, Nantes, France.
700    1_
$a Leviatan Ben-Arye, Shani $u Department of Cell Research and Immunology, The George S. Wise Faculty of Life Sciences, Tel Aviv University, Tel Aviv, Israel.
700    1_
$a Hruba, Petra $u Transplant Laboratory, Center for Experimental Medicine, Institute for Clinical and Experimental Medicine, Prague, Czech Republic.
700    1_
$a Slatinska, Janka $u Department of Nephrology, Transplant Center, Institute for Clinical and Experimental Medicine, Prague, Czech Republic.
700    1_
$a Evanno, Gwénaëlle $u Xenothera, Nantes, France.
700    1_
$a Duvaux, Odile $u Xenothera, Nantes, France.
700    1_
$a Blanchard, Dominique $u Xenothera, Nantes, France.
700    1_
$a Yu, Hai $u Department of Chemistry, University of California-Davis, Davis, California.
700    1_
$a Chen, Xi $u Department of Chemistry, University of California-Davis, Davis, California.
700    1_
$a Bach, Jean-Marie $u Immuno-Endocrinology Unit, EA4644 University/ONIRIS USC1383 INRA, Pathophysiology Department, ONIRIS-Nantes-Atlantic College of Veterinary Medicine and Food Sciences, Nantes, France.
700    1_
$a Padler-Karavani, Vered $u Department of Cell Research and Immunology, The George S. Wise Faculty of Life Sciences, Tel Aviv University, Tel Aviv, Israel.
700    1_
$a Viklicky, Ondrej $u Transplant Laboratory, Center for Experimental Medicine, Institute for Clinical and Experimental Medicine, Prague, Czech Republic. Department of Nephrology, Transplant Center, Institute for Clinical and Experimental Medicine, Prague, Czech Republic.
700    1_
$a Soulillou, Jean-Paul $u Centre de Recherche en Transplantation et Immunologie, UMR 1064, INSERM, Université de Nantes, Nantes, France. Institut de Transplantation Urologie Néphrologie (ITUN), CHU Nantes, Nantes, France.
773    0_
$w MED00009632 $t European journal of clinical investigation $x 1365-2362 $g Roč. 49, č. 4 (2019), s. e13069
856    41
$u https://pubmed.ncbi.nlm.nih.gov/30620396 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20200109 $b ABA008
991    __
$a 20200113152527 $b ABA008
999    __
$a ok $b bmc $g 1483330 $s 1083734
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2019 $b 49 $c 4 $d e13069 $e 20190225 $i 1365-2362 $m European journal of clinical investigation $n Eur J Clin Invest $x MED00009632
GRA    __
$p Ministry of Health, Czech Republic-conceptual development of research organization
GRA    __
$a Health-2013-INNOVATION-1-603049 $p FP7 Health
GRA    __
$a 62466 $p Israeli Ministry of Science, Technology and Space
LZP    __
$a Pubmed-20200109

Find record

Citation metrics

Archiving options